Effects of bicarbonate/lactate-buffered neutral peritoneal dialysis fluids on angiogenesis-related proteins in patients undergoing peritoneal dialysis

Hiromichi Ueno¹², Tetsu Miyamoto¹*, Hiroyuki Morimoto³, Kenya Sanada¹, Ikutaro Furuno¹, Kazutoshi Nakazono¹, Emi Hasegawa¹, Akihiro Kuma¹, Yasushi Oginosawa¹, Yuki Tsuda¹, Masaru Araki¹, Masahito Tamura⁴, Yoichi Ueta², Yutaka Otsuji¹ and Masaharu Kataoka¹

Abstract

Background: In order to facilitate the safe and long-term delivery of peritoneal dialysis (PD), it is necessary to improve the biocompatibility of peritoneal dialysis fluids (PDFs). The novel bicarbonate/lactate-buffered neutral PDFs (B/L-PDFs) are expected to be improved biocompatible. This study evaluated the biocompatibility of B/L-PDFs by analysis on the profile of angiogenesis-related proteins in drained dialysate of patients undergoing PD.

Methods: Concentrations of 20 angiogenesis-related proteins in the dialysate were semi-quantitatively determined using a RayBio® Human Angiogenesis Antibody Array and were compared between B/L-PDFs and conventional lactate-buffered neutral PDFs (L-PDFs).

Results: The expression of growth-related oncogene (GRO α/β/γ), which belongs to the CXC chemokine family, decreased significantly after use of the B/L-PDFs compared to the L-PDFs (P = 0.03). The number of the proteins with lower level in the B/L-PDFs compared with L-PDFs was significantly negatively correlated with the PD duration (Spearman ρ = −0.81, P = 0.004).

Conclusion: This study suggested that B/L-PDFs are more biocompatible than conventional PDFs.

Keywords: Bicarbonate/lactate-buffered neutral peritoneal dialysis fluid, Angiogenesis, Growth-related oncogene, Biocompatibility, Chemokine

Background

Peritoneal dialysis (PD), one of the major renal replacement therapies, has fewer cardiovascular events within several years after initiation compared to hemodialysis, and also excels in maintaining quality of life. Fluid retention and encapsulating peritoneal sclerosis (EPS) that occur as a result of peritoneal dysfunction prevent long-term delivery of PD [1]. Clinical and experimental evidence supports the view that continuous exposure to conventional PD fluids (PDFs) drives pathological alterations, including the loss of mesothelial cells, thickening of the submesothelial layer, and angiogenesis. Such inappropriate peritoneal remodeling ultimately leads to a high peritoneal solute transport rate, resulting in ultrafiltration failure and progressive loss of the dialyzing capacity of PD [2–5]. It is known that the deterioration of peritoneal tissue is associated with bioimcompatible
factors such as high glucose and lactate contents, high osmolality, glucose degradation products (GDPs) and low pH [6]. In particular, high lactate buffer content in PDFs is one of the important non-physiological factors that cause development of peritoneal membrane failure [7]. Despite lactate-buffered neutral PDFs (L-PDFs), which are used for majority of PD patients, having reportedly improved bioavailability, L-PDFs still include a high lactate content (40 mEq/L). Against this background, novel PDFs containing physiological concentrations (25 mEq/L) of sodium bicarbonate and low concentrations (10 mEq/L) of lactate (B/L-PDFs) have recently been developed.

Low-glucose degradation product bicarbonate/lactate-buffered solutions are reported to have less cell toxicity and superior cell viability in vitro, and less neoangiogenesis and impaired ultrafiltration in rat models of PD, as compared with low pH lactate-buffered solutions [8–10]. Kuma et al. reported a lactate-induced reduction in cell viability, showing that apoptosis of human peritoneal mesothelial cells was markedly induced by L-PDFs, but not by B/L-PDFs, which was attenuated by knockdown of monocarboxylate transporter-1, a cell membrane lactate transporter [11].

In clinical settings, although there was no difference in peritoneal equilibration tests and adequacy (PET) between B/L-PDFs and conventional lactate-buffered low pH PDFs, no consistent data on ultrafiltration are available [12–15]. Few reports have shown significant reductions in effluent levels of interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF), and increased cancer antigen 125 (CA125) in patients using B/L-PDFs, suggesting that B/L-PDFs may be better biocompatibility. However, these studies did not directly compare the effects of lactate as they were comparisons between B/L PDFs and conventional lactate-buffered acidic PDFs, not B/L PDFs and L-PDFs [16, 17].

As the most consistent change observed in the peritoneal tissue of PD-patients is submesothelial thickness coexisting with angiogenesis [18], it is relevant to study effluent levels of angiogenesis-related proteins to better understand the bioavailability of PDFs in clinical settings. We designed the present cross-over study to investigate the profile of angiogenesis-related proteins in drained dialysate of PD-patients.

Methods
Study design
We undertook an 8-week crossover trial of outpatients with maintenance PD (Fig. 1). The study was performed in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of the University Hospital of University of Occupational and Environmental Health School of Medicine, Japan (H26-245). Written informed consent was obtained from all participants. After enrollment, patients were randomly allocated to sequential treatment with L-PDFs (Dianeal N PD-4; Baxter Healthcare, Tokyo, Japan) following B/L-PDFs (Reguneal LCa; Baxter Healthcare) (group A, n = 5) or vice versa (group B, n = 5). The duration of each intervention was 4 weeks with a total study period of 8 weeks. Peritoneal equilibration tests (PET) were performed at baseline. After each intervention period, 100 ml of drained effluent after overnight dwell and blood samplings were collected.

Protein array analysis
Twenty angiogenesis-related proteins in drained effluents were semi-quantitively determined using the RayBio C-Series Human Angiogenesis Antibody Array according to manufacturer’s instructions (RayBiotech, Norcross, GA). The kit has been used in numerous studies and its reliability is guaranteed [19–21]. Briefly,
samples were incubated with an array membrane, followed by biotinylated antibodies. Biotinylated proteins captured by the membrane-bound antibodies were detected by incubation with horseradish peroxidase (HRP)-streptavidin and analysis using a chemiluminescence blot documentation system. The analyzed proteins with array map and representative image obtained from the procedure is shown in Fig. 2. Protein concentrations were expressed as the ratio (%) of the spot density to positive control density of each protein array membrane. Intermembrane normalization was performed using the signals for positive controls on each membrane. To validate data from the C-Series Antibody Array, Monocyte Chemotactic protein-1 (MCP-1) in the drained effluents was quantified using sandwich enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s instructions (Quantikine ELISA Kit, Human CCL2/MCP-1 Immunoassay; R&D Systems, Minneapolis, MN). We compared the spot density of MCP-1 obtained from the protein array analysis with the MCP-1 levels in ELISA, and noted a significant linear correlation between the levels obtained by protein array and ELISA (Fig. 3). In addition, GRO-α levels in the dialysate were quantified by using ELISA according to the manufacturer’s instructions (Quantikine® ELISA Human CXCL1/GROα Immuno assay; R&D system, Minneapolis, MN).

**Biochemical measurements**

At each time-point, blood (not fasting) was taken by venous puncture for measurement of albumin (Alb, g/dL), blood urine nitrogen (BUN, mg/dL), creatinine (Cre, mg/dL), calcium (Ca, mg/dL), phosphate (P, mg/dL), and hemoglobin (Hb, g/dL), using standard laboratory techniques.

**Statistics**

Spearman rank correlation analysis was used to determine the association between MCP-1 levels analyzed by protein array and by ELISA. Wilcoxon signed-rank test were used to assess treatment differences for angiogenesis-related proteins in effluents. Differences were considered statistically significant at $P < 0.05$. All statistical tests were performed using JMP version 12 (SAS Institute Inc., NC).

**Results**

**Study population**

Baseline characteristics of the 10 participants are summarized in Table 1. One of the 10 patients was female and 4 patients had diabetes mellitus. One patient was in the low PET category and 9 were in the high PET category.

**Table 1 Study population**

| No. | Sex | Age | Primary disease | PD duration (months) | Albumin (g/dL) | BUN (mg/dL) | Creatinine (mg/dL) | Calcium (mg/dL) | Phosphate (mg/dL) | Hemoglobin (g/dL) | PET category |
|-----|-----|-----|-----------------|---------------------|----------------|-------------|-------------------|----------------|----------------|-----------------|--------------|
| 1   | Male | 78  | HTN             | 26                  | 3.1           | 73          | 10.54             | 8.3            | 6.8            | 10.3            | HA           |
| 2   | Female | 52 | PCKD            | 1                   | 3.8           | 71          | 8.35              | 9.1            | 5.2            | 10.3            | Low          |
| 3   | Male | 66  | DN              | 39                  | 2.6           | 68          | 7.95              | 7.6            | 5.6            | 10.3            | HA           |
| 4   | Male | 76  | CGN             | 108                 | 3             | 58          | 9.9               | 8.4            | 6.2            | 13.1            | HA           |
| 5   | Male | 53  | DN              | 42                  | 3.7           | 43          | 8.6               | 8.6            | 4.3            | 11.6            | HA           |
| 6   | Male | 46  | HTN             | 50                  | 3.6           | 47          | 9.67              | 8.5            | 5.6            | 12.1            | HA           |
| 7   | Male | 64  | DN              | 44                  | 3.2           | 64          | 6.02              | 8.5            | 5.5            | 10.1            | HA           |
| 8   | Male | 69  | PCKD            | 20                  | 3.2           | 40          | 7.93              | 8.1            | 3.8            | 12              | HA           |
| 9   | Male | 70  | DN              | 7                   | 3.2           | 52          | 2.91              | 8.6            | 3.2            | 11.8            | HA           |
| 10  | Male | 65  | CGN             | 65                  | 3.6           | 73.5        | 11                | 9.5            | 5.7            | 10.2            | HA           |

*PD* peritoneal dialysis, *HTN* hypertensive nephrosclerosis, *PCKD* polycystic kidney disease, *DN* diabetic nephropathy, *CGN* chronic glomerulonephritis, *HA* high average, *BUN* blood urine nitrogen, *PET* peritoneal equilibration test
Fig. 4 (See legend on next page.)
category. During the study, there were no significant differences in body weight, blood pressure, serum albumin, blood urine nitrogen (BUN), creatinine, calcium, phosphate levels, and blood hemoglobin counts when either B/L-PDFs or L-PDFs were given.

Angiogenesis-related protein levels in drained effluents
Among the 20 evaluated angiogenesis-related proteins (Fig. 4), effluent levels of growth-regulated oncogene α/β/γ (GRO α/β/γ or CXCL1/2/3) decreased significantly after use of B/L-PDFs when compared with L-PDFs ($P = 0.03$). Levels of vascular endothelial growth factor-D (VEGF-D, $P = 0.11$) tended to be lower in B/L-PDFs than in L-PDFs. There were no angiogenesis-related proteins studied that showed significantly higher effluent levels with B/L-PDFs.

GRO-α levels in drained effluents
The level of GRO-α in B/L-PDFs were significantly lower than L-PDFs (Fig. 5).

Effects of dialysis duration on effluent angiogenesis-related protein levels
Dialysis vintage had a significantly negative correlation with the number of angiogenesis-related proteins that showed lower levels when using B/L-PDFs when compared with L-PDFs (Spearman $\rho = -0.81$, $P = 0.004$, Fig. 6).

Discussion
Neoangiogenesis in thickened peritoneal membrane is the major morphologic change induced by long-term exposure to PDFs, resulting in an expanded vascular network leading to reduced ultrafiltration capacity [2, 18, 22]. The present study directly evaluated the effects of lactate concentration by comparison between B/L-PDFs and L-PDFs, and showed that effluent levels of some angiogenesis-related proteins tended to be smaller in B/L-PDFs, especially in patients with shorter duration of PD. The kit has been used in numerous studies and its reliability is guaranteed. We demonstrated the accuracy and semi-quantitability of the kit by showing a significant linear correlation between MCP-1 levels measured by ELISA and MCP-1 levels measured by protein array. Several studies have shown that lactate stimulates angiogenesis in the context of the adaptive response contributing to cell preservation under hypoxic conditions [23, 24]. Although the molecular mechanisms remain elusive, bicarbonate-buffered neutral PDFs with low GDP content promotes less endothelial cell tube formation when compared to lactate-buffered neutral PDFs [25]. In rats, intraperitoneal exposure to lactate buffer, as compared with pH-adjusted bicarbonate buffer,
stimulates angiogenesis in the presence or absence of glucose [26]. These data support the results of the present study suggesting that high-dose lactate in PDFs may accelerate production of angiogenesis-related proteins in peritoneal membrane of PD patients. Chemokines have a critical role in angiogenesis or vascular remodeling [27]. GRO, a member of the CXC chemokine family with an internal glutamate-leucine-arginine (ELR) motif, has chemotactic and proangiogenic activities under inflammatory conditions [28]. Chemokines with an ELR motif, such as GRO and interleukin-8 (IL-8, CXCL-8), promote angiogenesis [29]. Interestingly, in this study, although no difference in effluent IL-8 levels was observed between B/L-PDFs and L-PDFs, GRO levels in the B/L PDFs group were clearly lower than with L-PDFs.

GRO has three highly homologous subtypes (α/β/γ). These three subtypes bind to the same receptor; however, they have different affinities and stimulate various physiological responses. In particular, GRO-α which is the chemokine (C-X-C motif) ligand 1 (CXCL1) has a three-dimensional structure similar to IL-8, and it has been reported that it has almost the same level of leukocyte migration ability compared with IL-8 [30, 31]. The level of GRO-α in B/L-PDFs was significantly lower than L-PDFs. This result supported that B/L-PDFs has improved biocompatibility compared to L-PDFs. VEGFs are key players in peritoneal neovascularization and lymphangiogenesis [22]. In this study, while density levels in effluents were higher in VEGF-D was more susceptible with L-PDFs. Terabayashi et al. recently reported that dialysate VEGF-D concentration was positively correlated with the dialysate to plasma ratio of creatinine (D/P Cr) and VEGF-D mRNA was significantly higher in the peritoneal membranes of patients with ultrafiltration failure [32]. VEGF-D may also be involved in the pathogenic process of lactate-induced peritoneal angiogenesis. To our knowledge, this is the first report showing a putative correlation between L-PDFs and GRO expression in peritoneal dialysate effluent of PD patients. To our knowledge, this is the first report to support that B/L-PDFs are more biocompatible PDFs than L-PDFs by examining the change of various angiogenesis-related proteins.

The number of angiogenesis-related proteins that decreased in the B/L PDFs group was significantly and negatively related to PD duration. Similar considerations were made for patient age, dialysis efficiency, and inflammatory markers. However, there was no correlation in any of the factors (data not shown). Notably, in two participants with less than 12 months of PD the densities of all proteins examined in this study were lower in the B/L PDFs group than with L-PDFs. Interestingly, despite the maintenance of peritoneal function by PET analysis, there may be differences in the benefits of using B/L PDFs by PD duration. Increasing peritoneal solute transport rate (PSTR) with duration of PD is often observed, which could be explained by an increase in the anatomic peritoneal membrane or an increase in the density of capillaries due to neoangiogenesis [33, 34].

Previous study reported that angiogenesis was suppressed in patients using lactate-buffered PDFs compared to patients using B/L-PDFs. However, many previous reports have compared L-acidic PDFs and B/L-neutral PDFs [16, 35, 36]. In the case of such a study design, pH differences could affect the results. The present study excluded the effect of pH and could demonstrate the high biocompatibility of B/L-PDFs.

Several limitations of the present study should be noted. First, due to the crossover design, the possibility of carry-over effects could not be removed, despite the fact that variation among participants was adequately prevented. Second, we did not examine the relationship between histological findings of the peritoneal membrane and effluent levels of the angiogenesis-related protein. Third, this study did not mechanically examine the involvement of GRO in the lactate-induced peritoneal angiogenesis.

Conclusions
The present study implies the possibility that B/L-PDFs suppress the lactate-induced production of proangiogenic proteins including CXC chemokines in peritoneal tissue, especially for the PD-patients on shorter duration of PD, suggesting that novel B/L-PDFs are more biocompatible than conventional L-PDFs. Further mechanical studies are warranted to elucidate the putative relation between lactate buffer and angiogenesis in peritoneal membrane in PD patients.

Abbreviations
B/L-PDFs: Bicarbonate/lactate-buffered neutral PDFs; BUN: Blood urea nitrogen; CA 125: Cancer antigen 125; D/P Cr: Dialysate to plasma ratio of creatinine; ELISA: Enzyme-linked immunosorbent assay; ELR: Internal glutamate-leucine-arginine; GRO α/β/γ: Growth-related oncogene; GDPs: Glucose degradation products; IL-6: Interleukin-6; IL-8: Interleukin-8; L-PDFs: Lactate-buffered neutral PDFs; MCP-1: Monocyte chemotactic protein-1; PSTR: Peritoneal dialysis; PDFs: Peritoneal dialysis fluids; PDGF-BB: Platelet-derived growth factor-BB; PET: Peritoneal equilibration tests and adequacy; PSTR: Peritoneal solute transport rate; VEGF-D: Vascular endothelial growth factor-D

Acknowledgements
The authors express their appreciation to Ms. Chizuko Oba and Ms. Hatsumi Nakamura for their assistance. This work was supported by a Grant-in-Aid for Scientific Research C (No. 18K11010) from the Japan Society for the Promotion of Science (JSPS).

Authors’ contributions
Design of the work: H.U., T.M., Y.O. The analysis: H.U., H.M., K.S., I.F., K.N., E.M., M.K. Interpretation of data: Y.O., Y.T., M.A., M.T., Y.U., Y.O. Drafted or revised the manuscript and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy are answered.
30. Moser B, Clark-Lewis I, Zwahlen R, Baggiolini M. Neutrophil-activating properties of the melanoma growth-stimulatory activity. J. Exp. Med. 1990; 171(5):1797–802. https://doi.org/10.1084/jem.171.5.1797.

31. Schumacher C, Clark-Lewis I, Baggiolini M, Moser B. High- and low-affinity binding of GRO-alpha and neutrophil-activating peptide 2 to interleukin 8 receptors on human neutrophils. Proc. Natl. Acad. Sci. U. S. A. 1992;89(21):10542–6. https://doi.org/10.1073/pnas.89.21.10542.

32. Terabayashi T, Ito Y, Mizuno M, Suzuki Y, Kinashi H, Sakata F, et al. Vascular endothelial growth factor receptor-3 is a novel target to improve net ultrafiltration in methylglyoxal-induced peritoneal injury. Lab. Invest. 2015; 95(9):1029–43. https://doi.org/10.1038/labinvest.2015.87.

33. Davies SJ. Longitudinal relationship between solute transport and ultrafiltration capacity in peritoneal dialysis patients. Kidney Int. 2004;66(6):2437–45. https://doi.org/10.1111/j.1523-1755.2004.66021.x.

34. Yu Z, Lambie M, Davies SJ. Longitudinal study of small solute transport and peritoneal protein clearance in peritoneal dialysis patients. Clin. J. Am. Soc. Nephrol. 2014;9(2):326–34. https://doi.org/10.2215/CJN.04420413.

35. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol. Dial. Transplant. 2004;19(8):2101–6. https://doi.org/10.1093/ndt/gfh326.

36. Perl J, Nessim SJ, Bargman JM. The biocompatibility of neutral pH, low-Ca²⁺ peritoneal dialysis solutions: benefit at bench, bedside, or both? Kidney Int. 2011;79(8):814–24. https://doi.org/10.1038/ki.2010.515.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.